BRPI0416289A - 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml) - Google Patents

4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)

Info

Publication number
BRPI0416289A
BRPI0416289A BRPI0416289-7A BRPI0416289A BRPI0416289A BR PI0416289 A BRPI0416289 A BR PI0416289A BR PI0416289 A BRPI0416289 A BR PI0416289A BR PI0416289 A BRPI0416289 A BR PI0416289A
Authority
BR
Brazil
Prior art keywords
cml
treatment
ome
quinolinecarbonitriles
anilino
Prior art date
Application number
BRPI0416289-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Frank Charles Boschelli
Jennifer Michele Golas
Kim Timothy Arnt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0416289A publication Critical patent/BRPI0416289A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0416289-7A 2003-11-06 2004-11-03 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml) BRPI0416289A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
PCT/US2004/036722 WO2005046693A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Publications (1)

Publication Number Publication Date
BRPI0416289A true BRPI0416289A (pt) 2007-01-23

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416289-7A BRPI0416289A (pt) 2003-11-06 2004-11-03 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)

Country Status (18)

Country Link
US (2) US7417148B2 (https=)
EP (1) EP1680119A1 (https=)
JP (1) JP2007533655A (https=)
KR (1) KR20060118461A (https=)
CN (1) CN1874776A (https=)
AU (1) AU2004289243B2 (https=)
BR (1) BRPI0416289A (https=)
CA (1) CA2543163A1 (https=)
CO (1) CO5690608A2 (https=)
CR (1) CR8350A (https=)
EC (1) ECSP066548A (https=)
IL (1) IL175424A0 (https=)
MX (1) MXPA06004744A (https=)
NO (1) NO20062255L (https=)
RU (1) RU2006113691A (https=)
SG (1) SG146681A1 (https=)
WO (1) WO2005046693A1 (https=)
ZA (1) ZA200603596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7468379B2 (en) 2005-06-17 2008-12-23 The Board Of Regents Of The University Of Texas System Inhibition of osteolytic lesions by SRC kinase inhibitors
KR20080027275A (ko) * 2005-06-24 2008-03-26 와이어쓰 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
HUE055524T2 (hu) * 2007-06-01 2021-11-29 Wyeth Llc A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
IN2014CH00840A (https=) 2014-02-20 2015-09-18 Apotex Inc
CN107530430A (zh) 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US12398355B2 (en) 2019-04-09 2025-08-26 Massachusetts Institute Of Technology Micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
SG146681A1 (en) 2008-10-30
US7919625B2 (en) 2011-04-05
JP2007533655A (ja) 2007-11-22
CN1874776A (zh) 2006-12-06
WO2005046693A1 (en) 2005-05-26
IL175424A0 (en) 2008-04-13
CO5690608A2 (es) 2006-10-31
US20100029677A1 (en) 2010-02-04
CR8350A (es) 2006-10-06
AU2004289243B2 (en) 2010-07-22
US7417148B2 (en) 2008-08-26
EP1680119A1 (en) 2006-07-19
ZA200603596B (en) 2009-12-30
MXPA06004744A (es) 2006-07-05
AU2004289243A1 (en) 2005-05-26
KR20060118461A (ko) 2006-11-23
ECSP066548A (es) 2006-10-17
NO20062255L (no) 2006-08-01
US20050101780A1 (en) 2005-05-12
CA2543163A1 (en) 2005-05-26
RU2006113691A (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
BRPI0416289A (pt) 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
BR0109851A (pt) Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
BR0109703A (pt) Derivados de piperazina
ATE300540T1 (de) Imidazopyridin-derivate
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE602005005240D1 (de) 4'-C-substituierte 2-Haloadenosinderivate
EA200801945A1 (ru) Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
ATE516326T1 (de) Kautschukmischungen
CY1112107T1 (el) Νεα ενωση πυριδαζινης και χρηση αυτης
CY1105766T1 (el) Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων
BRPI0507818A (pt) composto e métodos de inibição
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
ATE503746T1 (de) Neue imidazolidinderivate
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
BRPI0407441A (pt) 4-[(2,4-dicloro-5-metóxifenil)amino]-6-alcóxi-3-quinoli nacarbonitrilos para o tratamento de lesão isquêmica
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
TW200716650A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
BRPI0412159A (pt) emprego
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
BR0213465A (pt) Compostos de 4-imidazolin-2-ona
BR0102377A (pt) Inibidores de não-nucleosìdeo transcriptase reversa
TW200744589A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL